MENU

Fate Therapeutics FT819: Lupus Clinical Data and ACR 2026 Results

BioSpace USA
Overview
Fate Therapeutics reported that 100% of extrarenal lupus patients treated with FT819 without conditioning chemotherapy achieved measurable clinical responses. Safety data from 36 patients across four autoimmune indications showed no dose-limiting toxicities, supporting a shift toward outpatient administration and reduced chemotherapy reliance.
In Depth

Key Findings

Clinical data presented at ACR Convergence 2026 indicate that FT819 can induce meaningful responses in lupus patients without the use of conditioning chemotherapy. In a cohort of three extrarenal lupus patients treated under this regimen, two achieved the Definition of Remission in Systemic Lupus Erythematosus (DORIS) and one achieved Lupus Low Disease Activity State (LLDAS). Additionally, a patient treated with a two-dose regimen saw a reduction in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) by 8 points at Month 1, reaching LLDAS by Month 2 and sustaining it through Month 3.

Technical Details

The FT819 Phase 1 study evaluates three distinct regimens:

  • Regimen A: Single dose following fludarabine-free conditioning with cyclophosphamide or bendamustine.
  • Regimen B: Single dose without conditioning chemotherapy, added to stable background therapy.
  • Regimen C: Two doses (Day 1 and Day 15) following fludarabine-free conditioning.

As of August 18, 2026, 36 patients were treated, with 30 completing at least three months of follow-up. Outpatient administration was utilized for 12 of 36 patients (33%), with eight discharged the same day and four the following day. Safety data for outpatients was comparable to inpatient settings, with grade ≥3 treatment-emergent adverse events occurring in 16.7% of both groups and serious adverse events in 8.3% of both groups.

Background and Context

FT819 is an iPSC-derived cellular immunotherapy. Fate Therapeutics is also advancing FT839, a dual-CAR T cell targeting CD19 and CD38. Preclinical data for FT839 demonstrate the elimination of a broad spectrum of activated immune cells in rheumatoid arthritis models, supporting the goal of immune cell reset without conditioning chemotherapy.

Significance and Outlook

The ability to deliver FT819 as an outpatient therapy without intensive conditioning reduces barriers for autoimmune disease patients. These results inform the design of the RECLAIM-LN Phase 2 trial for lupus nephritis and the COMPLETE Phase 1/2 basket trial for FT839. The company’s scalable manufacturing process is intended to enable on-demand dosing and lower costs of goods.

Source: https://www.biospace.com/press-releases/fate-therapeutics-presents-new-ft819-data-at-acr-convergence-2026-highlighting-meaningful-clinical-responses-in-lupus-without-the-use-of-conditioning-chemotherapy

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC